Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Difenoxin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.74 |
| ▸ | KCNA3 | P22001 | 9/20 | 0.78 |
| ▸ | CCR1 | P32246 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | CCR3 | P51677 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Difenoxin SCHEMBL149008 | 0.99 | KCNA3 (0.76) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| Difenoxin SCHEMBL11604884 | 0.99 | KCNA3 (0.76) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| SCHEMBL9106795 | 0.93 | CCR1 (0.70) | KCNA3OPRM1CCR1CCR3 | |
| SCHEMBL11721054 | 0.91 | KCNA3 (0.66) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| SCHEMBL10064332 | 0.91 | KCNA3 (0.78) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| Diphenoxylate SCHEMBL8160138 | 0.90 | OPRM1 (0.94) | KCNA3OPRM1 | |
| Hydrochloric Acid SCHEMBL11604880 | 0.90 | KCNA3 (0.73) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| SCHEMBL11604250 | 0.90 | KCNA3 (0.84) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| SCHEMBL10065583 | 0.89 | KCNA3 (0.76) | KCNA3OPRM1CCR1RAB9ANPSR1 | |
| SCHEMBL10031241 | 0.88 | KCNA3 (0.74) | KCNA3OPRM1CCR1RAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2554 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122021-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF), THROUGH TARGETING OF S100A9 AND CORRESPONDING DIMER PARTNER AND RECEPTORS | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2025-06-12 | — | — | WO | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| US-20240083877-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | PURDUE RESEARCH FOUNDATION (US) | 2024-03-14 | — | — | US | claimed |
| US-20240016899-A1 | ORAL OCTREOTIDE FOR THE TREATMENT OF DISEASE | AMRYT ENDO INC (US) | 2024-01-18 | — | — | US | claimed |
| US-20230173034-A1 | ORAL OCTREOTIDE FOR THE TREATMENT OF DISEASE | AMRYT ENDO INC (US) | 2023-06-08 | — | — | US | claimed |
| US-20230158008-A1 | METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENTS | ACURA PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | claimed |
| CN-116148398-A | Method for detecting trace chemical hazard in fat-rich food | 北京市疾病预防控制中心 | 2023-05-23 | — | — | CN | claimed |
| US-20210187079-A1 | ORAL OCTREOTIDE FOR THE TREATMENT OF DISEASE | AMRYT ENDO, INC. | 2021-06-24 | — | — | US | claimed |
| US-6573282-B1 | Compositions for treatment of peripheral hyperalgesia are provided. The compositions contain an anti-hyperalgesia effective amount of one or more compounds that directly or indirectly interact with peripheral opiate receptors | ADOLOR CORPORATION | 2003-06-03 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6156771-A | Method for alleviation of lower gastrointestinal disorders in a human patient | RUBIN WALTER (US) | 2000-12-05 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-1024816-A1 | KITS AND METHODS FOR ALLEVIATION OF LOWER GASTROINTESTINAL DISORDERS IN A HUMAN PATIENT | Rubin, Walter (US) | 2000-08-09 | — | — | EP | claimed |
| WO-1999011277-A1 | KITS AND METHODS FOR ALLEVIATION OF LOWER GASTROINTESTINAL DISORDERS IN A HUMAN PATIENT | RUBIN WALTER (US) | 1999-03-11 | — | — | WO | claimed |
| EP-0852494-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-07-15 | — | — | EP | claimed |
| WO-1997009973-A2 | PERIPHERALLY ACTIVE ANTI-HYPERALGESIC OPIATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-03-20 | — | — | WO | claimed |
| WO-1992000082-A1 | ANTIDIARRHEAL COMPOSITIONS AND METHODS | THE PROCTER & GAMBLE COMPANY (US) | 1992-01-09 | — | — | WO | claimed |